As filed with the Securities and Exchange Commission on November 12, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
PYXIS ONCOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware |
83-1160910 |
(State or other jurisdiction of |
(I.R.S. Employer |
incorporation or organization) |
Identification Number) |
321 Harrison Avenue |
|
Boston, Massachusetts |
02118 |
(Address of Principal Executive Offices) |
(Zip Code) |
Pyxis Oncology, Inc. 2021 Equity and Incentive Plan
(Full title of the plan)
Lara Sullivan
President and Chief Executive Officer
Pyxis Oncology, Inc.
321 Harrison Avenue
Boston, Massachusetts 02118
(617) 221-9059
(Name, address, and telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
Non-accelerated filer |
☒ |
Smaller reporting company |
☒ |
|
|
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 5,500,000 shares of common stock, par value $0.001 per share (the “Common Stock”), of Pyxis Oncology, Inc., a Delaware corporation (the “Company” or the “Registrant”), to be issued pursuant to the First Amendment to the Pyxis Oncology, Inc. 2021 Equity and Incentive Plan (as amended, the “2021 Plan”), which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on October 22, 2021 (File No. 333-260441), March 29, 2022 (File No. 333-263950), March 22, 2023 (File No. 333-270753), and March 22, 2024 (File No. 333-278159) (collectively, the “Prior Form S-8s”).
This Registration Statement on Form S-8 relates to securities of the same class as that to which the Prior Form S-8s relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Form S-8s, to the extent relating to the registration of Common Stock issuable under the 2021 Plan, as applicable, are incorporated herein by reference and made part of this Registration Statement on Form S-8, except as amended hereby.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Commission:
All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”).
Any statement contained herein or in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any Current Report on Form 8-K, including the related exhibits under Item 9.01, that the Registrant may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.
Item 8. Exhibits.
The following exhibits are incorporated herein by reference:
Exhibit |
Description |
|
|
No. |
|
||
4.1 |
|
|
|
4.2 |
|
|
|
4.3 |
|
|
|
4.4 |
|
|
|
5.1* |
|
Opinion of Sidley Austin LLP with respect to the validity of issuance of securities |
|
23.1* |
|
|
|
23.2* |
|
|
|
24.1* |
|
Powers of Attorney (included on the signature page of the Registration Statement) |
|
107* |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Boston, Massachusetts, on the 12th day of November, 2024.
|
|
|
Pyxis Oncology, Inc. |
||
|
|
|
By: |
|
/s/ Lara Sullivan |
|
|
Lara Sullivan, M.D. |
|
|
President and Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lara Sullivan, M.D. and Pamela Connealy and each of them, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or such person’s substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/ Lara Sullivan |
|
President, Chief Executive Officer and Director |
|
November 12, 2024 |
Lara Sullivan, M.D. |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Pamela Connealy |
|
Chief Financial Officer and Chief Operating Officer |
|
November 12, 2024 |
Pamela Connealy |
|
(Principal Financial Officer) |
|
|
|
|
|
|
|
/s/ Jitendra Wadhane |
|
Chief Accounting Officer |
|
November 12, 2024 |
Jitendra Wadhane |
|
(Principal Accounting Officer) |
|
|
|
|
|
|
|
/s/ John Flavin |
|
Chairman of the Board of Directors |
|
November 12, 2024 |
John Flavin |
|
|
|
|
|
|
|
|
|
/s/ Thomas Civik |
|
Director |
|
November 12, 2024 |
Thomas Civik |
|
|
|
|
|
|
|
|
|
/s/ Darren Cline |
|
Director |
|
November 12, 2024 |
Darren Cline |
|
|
|
|
|
|
|
|
|
/s/ Freda Lewis-Hall, M.D. |
|
Director |
|
November 12, 2024 |
Freda Lewis-Hall, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Rachel Humphrey, M.D. |
|
Director |
|
November 12, 2024 |
Rachel Humphrey, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Jakob Dupont, M.D. |
|
Director |
|
November 12, 2024 |
Jakob Dupont, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Santhosh Palani, Ph.D., CFA |
|
Director |
|
November 12, 2024 |
Santhosh Palani, Ph.D., CFA |
|
|
|
|
|
|
|
|
|
/s/ Michael A. Metzger |
|
Director |
|
November 12, 2024 |
Michael A. Metzger |
|
|
|
|